Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Atom
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:bioavailability |
approximately 30%
|
| gptkbp:brand |
Nerlynx
|
| gptkbp:chemical_formula |
C28 H29 N3 O5 S
|
| gptkbp:class |
anilinoquinazoline
|
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:developed_by |
Puma Biotechnology
|
| gptkbp:discovery_year |
gptkb:2004
|
| https://www.w3.org/2000/01/rdf-schema#label |
neratinib
|
| gptkbp:indication |
gptkb:HER2-positive_breast_cancer
|
| gptkbp:marketed_as |
Puma Biotechnology
|
| gptkbp:mechanism_of_action |
tyrosine kinase inhibitor
|
| gptkbp:route_of_administration |
oral
|
| gptkbp:side_effect |
fatigue
nausea vomiting diarrhea rash |
| gptkbp:targets |
gptkb:HER2
|
| gptkbp:used_for |
gptkb:Oncology
|
| gptkbp:bfsParent |
gptkb:Erb_B_family
gptkb:Lapatinib gptkb:HER2-positive_breast_cancer |
| gptkbp:bfsLayer |
6
|